Archives of Clinical Infectious Diseases
Infectious Diseases and Tropical Medicine Research Center, SBUMS
Authors
Vulvovaginal candidiasis (VVC) is a fungal infection of the vagina and vulva. It is usually caused by Candida albicans, however, occasionally other candida species are responsible. The optimal treatment of VVC has not yet been defined. The present study was designed to compare the efficacy and safety of a single oral dose of fluconazole with clotrimazole vaginal cream as the treatment of choice for recurrent VVC.
We conducted a clinical trial study on 124 women with RVVC. Sampling of vaginal discharge was achieved for clinically suspected patients, then, observed with KOH for vaginal candidiasis. Sample culture was performed for cases in whom the result of direct examination was negative but there was high clinical suspicion of the disease. For laboratory examination, swab specimens were placed on sabourauds agar plus chloramphenicol and cyclohexamide with natural PH. For treatment, patients were randomized systematically in 2 equal groups, one receiving clotrimazole vaginal cream 5g/day for 7 days for acute episode and 5g twice a week for 6 months as a prophylaxis. The second group was prescribed single oral dose of fluconazole capsule 150 mg for acute episode followed by prophylactic regimen of 150 mg weekly for 6 months.
A total of 124 women with RVVC were enrolled and assigned in 2 groups of fluconazole and clotrimazole with the mean age of 325 years (a range, 18-50 years) and 322 years (a range, 19-49 years), respectively. Of 117 cases, the recurrence rate was 8.6% in fluconazole and 8.5% in clotrimazole group. Recurrence rate in follow up period (second 6 months) was 38.3% and 40%, respectively (NS).
Response to treatment and reduction in recurrence rate of VVC were similar among fluconazole and longterm users of azole vaginal creams
© 2007, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Khorsandi M, Modares Gilani M, Khosravi A. Treatment and recurrence of vaginal candidiasis after oral and intravaginal treatment. J Inflamm Dis. 2024;4(2):e154708. doi:
Bolouri F, Moghadami Tabrizi N, Davari Tanha F, Azmoodeh A, Emami S, et al. Effectiveness of Fluconazole for Suppressive Maintenance Therapy in Patients with RVVC: a Randomized Placebo-Controlled Study. Iran J Pharm Res. 2022;8(4):e128654. doi: https://doi.org/10.22037/ijpr.2010.827
Karimaan N, Shafaaii Z, Afraakhte M, Valaaii N, Ahmadi M. Comparing Fluconazole and Clotrimazole in treatment of candida albicans vaginitis. J Kermanshah Univ Med Sci. 2002;6(3):e81013. doi:
Deravi N, Fathi M, Tabatabaeifar SN, Pooransari P, Ahmadi B, et al. Azole Antifungal Resistance in Candida albicans and Candida glabrata Isolated from Vulvovaginal Candidiasis Patients. Arch Clin Infect Dis. 2021;16(2):e106360. doi: https://doi.org/10.5812/archcid.106360
Hedayati MT, Taheri Z, Galinimoghadam T, Aghili SR, Yazdani Cherati J, et al. Isolation of Different Species of Candida in Patients With Vulvovaginal Candidiasis From Sari, Iran. Jundishapur J Microbiol. 2015;8(4):e15992. doi: https://doi.org/10.5812/jjm.8(4)2015.15992
Last Update: 1 month ago
Last Update: 1 month ago
Last Update: 1 month ago
Last Update: 3 days ago